WooGene B&G Co., Ltd (KOSDAQ:018620)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,730.00
+170.00 (4.78%)
At close: Apr 27, 2026
-17.39%
Market Cap 21.55B
Revenue (ttm) 54.76B
Net Income (ttm) -1.77B
Shares Out 5.78M
EPS (ttm) -305.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,693
Average Volume 22,005
Open 3,620.00
Previous Close 3,560.00
Day's Range 3,585.00 - 3,730.00
52-Week Range 3,325.00 - 5,230.00
Beta 0.38
RSI 54.60
Earnings Date May 12, 2026

About WooGene B&G

WooGene B&G Co., Ltd. engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. It offers antibiotic, vaccine, nutrient, anti-inflammation, metabolic stimulant, and iron supplement products for swine, poultry, cattle, aquatic animals, companion animals, and raw materials, as well as operates vaccine research center. The company was formerly known as WooJin Co., Ltd. and changed its name to WooGene B&G Co., Ltd. in March 2001. WooGene B&G Co., Ltd. was founded in 1977 and is headquartered in Hw... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 92
Stock Exchange KOSDAQ
Ticker Symbol 018620
Full Company Profile

Financial Performance

In 2025, WooGene B&G's revenue was 54.76 billion, a decrease of -1.65% compared to the previous year's 55.68 billion. Losses were -1.77 billion, -66.03% less than in 2024.

Financial Statements

News

There is no news available yet.